(Q34619908)

3 August 2017

1 reference

title

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

1 reference

Weidong Xu

1 reference

3 August 2017

Regina Hofmann-Lehmann

series ordinal

1 reference

3 August 2017

Harold M McClure

series ordinal

1 reference

3 August 2017

Ruth M Ruprecht

series ordinal

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

1956-1960

1 reference

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Animal models for the study of human immunodeficiency virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Advances and research directions in the prevention of mother-to-child HIV-1 transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Reducing the risk of maternal-infant transmission of HIV by attacking the virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Exposure to HIV-1 during delivery and mother-to-child transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

HIV transmission through breastfeeding: a study in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900077-4

7 January 2021

10.1016/S0264-410X(02)00077-4

Identifiers

DOI

1 reference

3 August 2017

1 reference